Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13486398 | 0.83 | PDE4B (0.34) | EIF2AK4 | |
| SCHEMBL19366756 | 0.83 | PDE4B (0.34) | EIF2AK4 | |
| SCHEMBL19366754 | 0.83 | PDE4B (0.34) | EIF2AK4 | |
| SCHEMBL21103552 | 0.78 | EIF2AK4 (0.35) | VNN1EIF2AK4 | |
| SCHEMBL19708769 | 0.78 | HTR2A (0.39) | VNN1EIF2AK4 | |
| SCHEMBL12563401 | 0.75 | PDCD1LG2 (0.32) | VNN1 | |
| SCHEMBL18849760 | 0.75 | PDCD1LG2 (0.32) | VNN1 | |
| SCHEMBL18849759 | 0.75 | PDCD1LG2 (0.32) | VNN1 | |
| SCHEMBL27420770 | 0.74 | SOS1 (0.35) | VNN1PIK3CDEIF2AK4 | |
| SCHEMBL23441864 | 0.73 | VNN1 (0.34) | VNN1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10723733-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10640511-B2 | Hepatitis B antiviral agents | Enant Pharmaceuticals, Inc. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-04-25 | — | — | US | disclosed |
| US-10189846-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | VNN1 3392/4885PIK3CD 1573/4885EIF2AK4 637/4885 |
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | VNN1 3392/4885PIK3CD 1573/4885EIF2AK4 637/4885 |
| US-10189846-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | VNN1 3392/4885PIK3CD 1573/4885EIF2AK4 637/4885 |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | VNN1 3392/4885PIK3CD 1573/4885EIF2AK4 637/4885 |
| US-10723733-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | VNN1 3392/4885PIK3CD 1573/4885EIF2AK4 637/4885 |
| US-10640511-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | VNN1 3392/4885PIK3CD 1573/4885EIF2AK4 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.